256 related articles for article (PubMed ID: 36792381)
41. Molecular genetics of cocaine use disorders in humans.
Fernàndez-Castillo N; Cabana-Domínguez J; Corominas R; Cormand B
Mol Psychiatry; 2022 Jan; 27(1):624-639. PubMed ID: 34453125
[TBL] [Abstract][Full Text] [Related]
42. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
43. Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications.
Zhang MW; Harris KM; Ho RC
BMC Med Ethics; 2016 Jan; 17():4. PubMed ID: 26768892
[TBL] [Abstract][Full Text] [Related]
44. Medical conditions of primary care patients with documented cannabis use and cannabis use disorder in electronic health records: a case control study from an academic health system in a medical marijuana state.
Padwa H; Huang D; Mooney L; Grella CE; Urada D; Bell DS; Bass B; Boustead AE
Subst Abuse Treat Prev Policy; 2022 May; 17(1):36. PubMed ID: 35527269
[TBL] [Abstract][Full Text] [Related]
45. A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study.
Dakwar E; Nunes EV; Hart CL; Hu MC; Foltin RW; Levin FR
Neuropharmacology; 2018 Nov; 142():270-276. PubMed ID: 29309770
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of the 5-HT
Jastrzębska J; Frankowska M; Smaga I; Hubalewska-Mazgaj M; Suder A; Pieniążek R; Przegaliński E; Filip M
Pharmacol Rep; 2023 Feb; 75(1):99-118. PubMed ID: 36374478
[TBL] [Abstract][Full Text] [Related]
47. Mechanisms of ketamine action as an antidepressant.
Zanos P; Gould TD
Mol Psychiatry; 2018 Apr; 23(4):801-811. PubMed ID: 29532791
[TBL] [Abstract][Full Text] [Related]
48. Ketamine's dose related multiple mechanisms of actions: Dissociative anesthetic to rapid antidepressant.
Lavender E; Hirasawa-Fujita M; Domino EF
Behav Brain Res; 2020 Jul; 390():112631. PubMed ID: 32437885
[TBL] [Abstract][Full Text] [Related]
49. Patient perspectives on current and potential therapies and clinical trial approaches for cocaine use disorder.
Maahs S; Leclair D; Gomez-Mancilla B; Kiluk BD; Muthusamy VS; Banerjee PS; Dasgupta S; Waye KM
Front Psychiatry; 2024; 15():1230699. PubMed ID: 38487570
[TBL] [Abstract][Full Text] [Related]
50. Hypertensive Crisis-Related Hospitalizations and Subsequent Major Adverse Cardiac Events in Young Adults with Cannabis Use Disorder: A Nationwide Analysis.
Desai R; Jain A; Sultan W; Gandhi Z; Raju AR; Varughese VJ; Jnaneswaran G; Agarwal C; Rizvi B; Mansuri Z; Gupta P; Kumar G; Sachdeva R
Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295625
[TBL] [Abstract][Full Text] [Related]
51. Plasma Lysophosphatidic Acid Concentrations in Sex Differences and Psychiatric Comorbidity in Patients with Cocaine Use Disorder.
Requena-Ocaña N; Flores-López M; García-Marchena N; Pavón-Morón FJ; Pedraza C; Wallace A; Castilla-Ortega E; Rodríguez de Fonseca F; Serrano A; Araos P
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958570
[TBL] [Abstract][Full Text] [Related]
52. Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications.
Cohen IV; Makunts T; Atayee R; Abagyan R
Sci Rep; 2017 May; 7(1):1450. PubMed ID: 28469132
[TBL] [Abstract][Full Text] [Related]
53. Antidepressants in pregnancy: applying causal epidemiological methods to understand service-use outcomes in women and long-term neurodevelopmental outcomes in exposed children.
Heuvelman H; Davies NM; Ben-Shlomo Y; Emond A; Evans J; Gunnell D; Liebling R; Morris R; Payne R; Storey C; Viner M; Rai D
Health Technol Assess; 2023 Sep; 27(15):1-83. PubMed ID: 37842916
[TBL] [Abstract][Full Text] [Related]
54. Abnormal neuroanatomical patterns as potential diagnostic biomarkers for cocaine use disorder.
Xu H; Xu C; Guo Y; Hu Y; Bai G; Du M
Addict Biol; 2023; 28(11):e13348. PubMed ID: 37855070
[TBL] [Abstract][Full Text] [Related]
55. Impaired neural response to negative prediction errors in cocaine addiction.
Parvaz MA; Konova AB; Proudfit GH; Dunning JP; Malaker P; Moeller SJ; Maloney T; Alia-Klein N; Goldstein RZ
J Neurosci; 2015 Feb; 35(5):1872-9. PubMed ID: 25653348
[TBL] [Abstract][Full Text] [Related]
56. Treatment-resistant depression as risk factor for substance use disorders-a nation-wide register-based cohort study.
Brenner P; Brandt L; Li G; DiBernardo A; Bodén R; Reutfors J
Addiction; 2019 Jul; 114(7):1274-1282. PubMed ID: 30938020
[TBL] [Abstract][Full Text] [Related]
57. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
[TBL] [Abstract][Full Text] [Related]
58. Acute impact of self-guided mental imagery on craving in cocaine use disorder: a mixed-methods analysis of a randomized controlled trial.
Lowry N; Marsden J; Clydesdale B; Eastwood B; Havelka EM; Goetz C
Addiction; 2021 Sep; 116(9):2418-2430. PubMed ID: 33405313
[TBL] [Abstract][Full Text] [Related]
59. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model.
Smits KM; Smits LJ; Schouten JS; Peeters FP; Prins MH
Clin Ther; 2007 Apr; 29(4):691-702. PubMed ID: 17617292
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis.
Torrens M; Fonseca F; Mateu G; Farré M
Drug Alcohol Depend; 2005 Apr; 78(1):1-22. PubMed ID: 15769553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
